MedTrace Logo

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

NCT07635186 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-07-29

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.

Conditions

Interventions

DRUG

AHB-137

AHB-137 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Sponsors & Collaborators

  • Ausper Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yunqing Qiu · First Affiliated Hospital of Zhejiang University

  • Peng Hu · The Second Affiliated Hospital of Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-05
Primary Completion
2027-06-20
Completion
2028-06-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07635186 on ClinicalTrials.gov